Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
19.85
-0.65 (-3.17%)
Jan 27, 2026, 4:00 PM EST - Market closed
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $179.52M in the quarter ending September 30, 2025, with 6.49% growth. This brings the company's revenue in the last twelve months to $716.79M, up 3.14% year-over-year. In the year 2024, Pacira BioSciences had annual revenue of $700.97M with 3.85% growth.
Revenue (ttm)
$716.79M
Revenue Growth
+3.14%
P/S Ratio
1.26
Revenue / Employee
$907,330
Employees
790
Market Cap
853.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 700.97M | 25.99M | 3.85% |
| Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
| Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
| Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
| Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
| Dec 31, 2019 | 421.03M | 83.75M | 24.83% |
| Dec 31, 2018 | 337.28M | 50.65M | 17.67% |
| Dec 31, 2017 | 286.63M | 10.26M | 3.71% |
| Dec 31, 2016 | 276.37M | 27.37M | 10.99% |
| Dec 31, 2015 | 249.00M | 51.33M | 25.97% |
| Dec 31, 2014 | 197.67M | 112.12M | 131.05% |
| Dec 31, 2013 | 85.55M | 46.47M | 118.89% |
| Dec 31, 2012 | 39.08M | 23.40M | 149.12% |
| Dec 31, 2011 | 15.69M | 1.13M | 7.74% |
| Dec 31, 2010 | 14.56M | -444.00K | -2.96% |
| Dec 31, 2009 | 15.01M | 1.08M | 7.76% |
| Dec 31, 2008 | 13.93M | 5.58M | 66.95% |
| Dec 31, 2007 | 8.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evotec SE | 887.40M |
| Tilray Brands | 837.32M |
| Emergent BioSolutions | 788.90M |
| Collegium Pharmaceutical | 757.07M |
| Amphastar Pharmaceuticals | 723.31M |
| BioCryst Pharmaceuticals | 599.82M |
| Ironwood Pharmaceuticals | 338.99M |
| Esperion Therapeutics | 303.80M |
PCRX News
- 13 days ago - Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets - GlobeNewsWire
- 19 days ago - Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues - GlobeNewsWire
- 20 days ago - Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences - GlobeNewsWire
- 4 weeks ago - DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. - PRNewsWire
- 7 weeks ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical - GlobeNewsWire
- 2 months ago - Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - GlobeNewsWire